Duloxetine for major depressive disorder and stress urinary incontinence
Canadian Coordinating Office for Health Technology Assessment
Record ID 32004000800
English, French
Authors' objectives:
To summarize the available information on the use of duloxetine hydrochloride (Trade Mark: Cymbalta) for the treatment of major depressive disorder and stress urinary incontinence in women.
Authors' recommendations:
Duloxetine is another choice in the growing list of marketed antidepressants. Trials comparing duloxetine with appropriate doses of comparators are lacking. Direct evidence of a long-term benefit is also lacking. Duloxetine is a novel choice for the treatment of stress urinary incontinence, but comparative trials demonstrating its effectiveness relative to other agents are lacking. The high incidence of treatment withdrawal due to nausea may limit the use of duloxetine in practice.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antidepressive Agents
- Depressive Disorder
- Urinary Incontinence, Stress
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.